IL-4Rαflox/− mice were treated i.t. with 3 µg of IL-13 daily for 7 days. A. Invasive measurement of AHR. B. Absolute eosinophil count of BAL fluid. C. Quantitation of goblet cell metaplasia (GCM). D. Distribution of residual GCM in club cell 10 kDa protein-Cre+ (CC10-Cre+) mice and CC10-Cre+ α-smooth muscle actin-Cre+ (SMP8-Cre+) mice. E. Absolute eosinophil count of BAL fluid in CC10-Cre+ and CC10-Cre+SMP8-Cre+ mice that had high or low residual GCM. F. Percentage of eosinophils in BAL fluid in CC10-Cre+ mice and CC10-Cre+SMP8-Cre+ that had high or low residual GCM. G, AHR when CC10-Cre+ and CC10-Cre+SMP8-Cre+ mice that had high residual GCM were excluded. The results represent 12 pooled experiments with panels A-D showing 17, 14, 26, 22 and 47 mice for groups: Cre− + IL-13, SMP8-Cre+ + IL-13, CC10-Cre+ + IL-13, Both Cre+ + IL-13, all genotypes + saline, respectively. Panel G represents 14 and 12 mice for groups: CC10-Cre+ + IL-13 and both Cre+ + IL-13, respectively. NS, not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.